INDIA: In response to an alert issued by the Indian Pharmacopoeia Commission (IPC), medical experts advise caution regarding the use of Meftal, a common painkiller utilized for various conditions, including menstrual cramps, rheumatoid arthritis, and dental pain.
IPC Alert Highlights Adverse Reactions
The IPC alert emphasizes potential adverse reactions associated with Meftal, particularly due to its main composition, Mefenamic acid. The alert warns of the risk of Eosinophilia and systemic symptoms (DRESS) syndrome, a severe allergic disease recognized for its painful manifestations.
DRESS syndrome involves an extensive skin rash accompanied by organ involvement, Lymphadenopathy, Eosinophilia, and systemic manifestations. Dr. Tushar Tayal, Lead Consultant at CK Birla Hospital, Gurugram, explains the challenging nature of predicting DRESS syndrome, urging caution in over-the-counter painkiller usage.
Risks of Mefenamic Acid as an NSAID
Mefenamic acid, classified as a nonsteroidal anti-inflammatory drug (NSAID), carries inherent risks and side effects. These include gastrointestinal issues, cardiovascular complications, and renal problems. Dr. Vikramjeet Singh from Aakash Healthcare underscores the need for caution in patients with kidney disease, epilepsy, or cardiac dysfunction.
Doctors emphasize a cautious approach, advocating for the lowest effective dose for the shortest duration when administering NSAIDs like Meftal. Dr. Rashmi Baliyan from Primus Super Speciality Hospital highlights the unsuitability of Meftal for pregnant and nursing women, citing potential disruptions to blood flow to the fetus and toxicity in breast milk.
Meftal Concerns Extend to Childhood Usage
Dr. Rajath Athreya from Sakra World Hospital Bengaluru raises concerns over Meftal’s use for childhood fevers, emphasizing the lack of safety data to support its benefits. He encourages a tiered approach, prioritizing trusted medications like paracetamol and occasional ibuprofen.
The collective advice from health experts underscores the importance of seeking professional medical advice before using Meftal or any medication. They urge patients to understand potential risks and receive personalized guidance for safe usage.
As the IPC’s drug safety alert prompts increased awareness, healthcare professionals and patients are encouraged to stay informed and exercise caution in medication choices.
The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.
Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.
The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.